A major new UK‑wide research collaboration has launched to accelerate the development of promising new treatments and precision diagnostics for Parkinson’s disease and other neurological conditions affecting movement.
The Parkinson’s Disease Translational Research Collaboration (PD‑TRC), funded by the National Institute for Health and Care Research and supported by four leading charities, is the first of eight NIHR Translational Research Collaborations to focus specifically on Parkinson’s disease.
The PD‑TRC has been established to bring together the UK’s expertise, facilities and infrastructure to overcome long‑standing barriers in Parkinson’s research.
Delivered through 17 centres of excellence across the NHS and academia, the collaboration aims to strengthen coordination and scale up translational research – the critical stage that tests the safety, effectiveness and real‑world impact of new scientific discoveries.
Translational research bridges the gap between laboratory science and patient benefit, helping ensure innovations are developed, trialled and adopted more quickly.
Parkinson’s disease is a complex neurodegenerative condition that affects more than 166,000 people in the UK.
Despite advances in basic science, progress in Parkinson’s research has been slowed by:
- Gaps in experimental medicine and early‑stage clinical trials
- Fragmented research across separate disciplines
- Limited national coordination of specialist expertise
The PD‑TRC is designed to tackle these challenges by fostering collaboration between basic science, experimental medicine and clinical research.
The new Translational Research Centre is led by Professor Oliver Bandmann, Honorary Consultant Neurologist at Sheffield Teaching Hospitals NHS Foundation Trust and Professor of Movement Disorders at the University of Sheffield.
He is supported by Professor Camille Carroll from the NIHR Newcastle Biomedical Research Centre, and Professor Alistair Noyce from Queen Mary University of London, both internationally recognised leaders in Parkinson’s research.
Commenting on this development, Professor Bandmann:
“Parkinson’s Disease can be devastating for those that live with it, and despite progress in treatment and detection we still haven’t found treatment to slow down the disease and address every patient’s needs.
“This is why this new NIHR-funded Translational Research Collaboration with specific focus on Parkinson’s and related disorders is so important. When experts collaborate, barriers can be overcome, and great things can happen. We also have strong support from all relevant patient charities. Furthermore, people with Parkinson’s will be closely involved to ensure that their voice will be heard. I am excited for what we can achieve.
“The NIHR-PD-TRC represents a unique opportunity to transform early-phase clinical research in Parkinson’s disease and related disorders in the UK. It aims to bridge the gap between promising preclinical discoveries and clinical trials.”
The collaboration is hosted by the NIHR Sheffield Biomedical Research Centre, marking the first time a Parkinson’s‑focused TRC has been based there.
PD‑TRC is the eighth Translational Research Collaboration established by the NIHR, with two launched in the past year alone.
Together, the TRCs form a national network designed to accelerate research progress in areas of high unmet need, strengthening the UK’s position as a global leader in health research.
A core ambition of the PD‑TRC is to act as a central hub for collaboration across:
- Academic research
- NHS clinical services
- Industry partners
- Parkinson’s charities and patient organisations
By working closely with industry and the third sector, the collaboration aims to speed up development timelines, widen access to research opportunities and ensure studies reflect patient priorities.
Leaders say this collaborative model will also help reduce inequalities in research access, ensuring patients across the UK can benefit from innovation regardless of where they live.
By aligning expertise and resources nationally, the PD‑TRC aims to:
- Speed up early‑phase clinical trials
- Improve development of precision diagnostics
- Translate discoveries into meaningful patient benefits faster
The NIHR said the initiative represents a decisive step towards closing the gap between scientific discovery and real‑world impact for people living with Parkinson’s disease.
Image credit: iStock
